Editas Medicine Appoints Dan Ory Chief Medical Officer
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The appointment of an experienced Chief Medical Officer is viewed positively for Editas Medicine's clinical development prospects, though the stock showed a slight pre-market decline. The move signals continued progress toward advancing EDIT-401 into clinical trials, which could impact the company's valuation in the near term.
Editas Medicine, a U.S. gene editing company, announced on September 8, 2026, the appointment of Dan Ory, M.D., as Chief Medical Officer, effective immediately. Dr. Ory, a biotechnology executive with over 25 years of experience in cardiovascular and genetic medicine, will oversee clinical development strategy and operations as Editas advances its lead in vivo candidate, EDIT-401 for hyperlipidemia, toward the clinic. Prior to joining Editas, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies and Casma Therapeutics, and spent over two decades at Washington University School of Medicine. The appointment strengthens Editas's executive leadership team as it progresses its gene editing pipeline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard